Permira launches Neuraxpharm sale as lenders line up $1.8bn of buyout debt ' Private Equity Insights
Banks and private credit firms are competing to provide financing packages ranging from about '1bn to '1.5bn. That would represent roughly 5.5x to 8x Neuraxpharm's Ebitda, which stood at about '170m to '200m last year. The debt is expected to be structured primarily as senior leveraged loans, with the potential inclusion of junior debt. The competition among lenders reflects renewed confidence in leveraged finance markets after a rebound in M&A activity in the second half of 2025. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today.
learn more
